跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
許 銘能
助理教授
藥學系
電話
(02) 2826-7985
電子郵件
mnshiu
nycu.edu
tw
h-index
h10-index
h5-index
632
引文
11
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
154
引文
8
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
68
引文
3
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2000
2025
每年研究成果
概覽
指紋
網路
研究成果
(33)
類似的個人檔案
(6)
指紋
查看啟用 Ming-Neng Shiu 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Taiwan
100%
Malignant Transformation
28%
Leukoplakia
26%
Psoriasis
25%
Oral Cancer
19%
Risk Factors
17%
Population-based
17%
Emergency Department Length of Stay
17%
Emergency Department
17%
Length of Stay
17%
Community-based
17%
Combined Test
17%
National Cohort Study
17%
Varenicline
17%
Cost-effectiveness Analysis
17%
Smoking Cessation
16%
Natural History of Disease
16%
National Health Insurance
15%
Screening Program
14%
Quality of Care
14%
Emergency Room
13%
Public Health
13%
Integrated Screening
12%
Alcohol
12%
Odds Ratio
12%
Betel Quid
11%
Confidence Interval
11%
Patients with Hypertension
10%
Transition Rates
10%
Psoriatic Arthritis
10%
Older Patients
10%
Chronic Disease
9%
Tobacco Control
9%
Long-term Care Facilities
9%
Home Care
9%
Disease Screening
9%
Preventive Medicine
8%
Unresectable Hepatocellular Carcinoma
8%
Enterovirus
8%
Antibiotic Use
8%
Behavioral Intention
8%
Regulatory Science
8%
Fecal Occult Blood Test
8%
Risk Assessment
8%
Evaluation of Care
8%
Smoking Cessation Intervention
8%
Di-(2-ethylhexyl) Phthalate
8%
Older Smokers
8%
Nicotine Replacement Therapy
8%
Cardiovascular Risk
8%
Medicine and Dentistry
Diseases
28%
Cohort Analysis
25%
Malignant Transformation
17%
Emergency Department
17%
Leukoplakia
17%
Psoriasis
17%
Screening
17%
Public Health
12%
Triage
11%
Cross Sectional Study
10%
Patient with Hypertension
10%
Diastolic Blood Pressure
8%
Nicotine Withdrawal
8%
Observational Study
8%
Avascular Necrosis
8%
Mouth Carcinoma
8%
Cardiovascular Procedure
8%
Long-Term Care
8%
Varenicline
8%
Cardiovascular Risk
8%
Preventive Medicine
8%
Health Information System
8%
Oral Cancer
8%
Pemigatinib
8%
Primary Health Care
8%
Hormone Therapy
8%
Care Group
8%
Cardiovascular Surgery
8%
Health Care Cost
8%
Cholangiocarcinoma
8%
Targeted Therapy
8%
Biological Marker
8%
Cost-Effectiveness Analysis
8%
Antibiotic Therapy
8%
Antibiotics
8%
Womens Health
8%
Human Immunodeficiency Virus Infection
8%
Antiretroviral Therapy
8%
Acquired Immune Deficiency Syndrome
8%
Medical Care
8%
Cardiovascular Disease
7%
Comorbidity
7%
Neoplasm
7%
Decubitus
6%
Hazard Ratio
6%
Systolic Blood Pressure
6%
Common Cold
5%
Betel
5%
Infection
5%
Chronic Disease
5%
Nursing and Health Professions
Diseases
20%
National Health Insurance
18%
Nicotine Withdrawal
17%
Varenicline
17%
Emergency Ward
17%
Length of Stay
17%
Screening
17%
Prevalence
14%
Home Care
12%
Cross-Sectional Study
11%
Nurse
11%
Triage
9%
Tobacco Control
9%
Hospital
9%
Long Term Care
9%
Primary Medical Care
9%
Patient Referral
8%
Cost Effectiveness Analysis
8%
Diastolic Blood Pressure
8%
Antibiotic Therapy
8%
Nicotine Replacement Therapy
8%
Occult Blood
8%
Sorafenib
8%
Bevacizumab
8%
Immigrant Woman
8%
Cohort Analysis
8%
Quality Control
8%
Malignant Transformation
8%
Mouth Carcinoma
8%
Leukoplakia
8%
Liver Cell Carcinoma
8%
Compliance
8%
Cardiovascular Risk
8%
Avascular Necrosis
8%
Psoriasis
8%
Hormonal Therapy
8%
Occult Blood Test
8%
Neoplasm
7%
Institutional Care
7%
Care Group
7%
Confidence Interval
7%
Chronic Disease
6%
Systolic Blood Pressure
6%
Cardiovascular Disease
6%
Comorbidity
5%
Common Cold
5%
Pressure Ulcer
5%
Nutrition Policy
5%
Quality Adjusted Life Year
5%
Logistic Regression Analysis
5%
